Decitabine is a hypomethylating agent. It hypomethylates DNA by inhibiting DNA methyltransferase.

It functions in a agnate address to azacitidine, although decitabine can alone be congenital into DNA strands while azacitidine can be congenital into both DNA and RNA chains.

Decitabine is adumbrated for the analysis of myelodysplastic syndromes (MDS) including ahead advised and untreated, de novo and accessory MDS of all French-American-British subtypes (refractory anemia, adverse anemia with belted sideroblasts, adverse anemia with balance blasts, adverse anemia with balance blasts in transformation, and abiding myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups. In patients with renal insufficiency, Batty and colleagues appear the aboriginal case alternation on the achievability of analysis with hypomethylating agents in patients with renal insufficiency.